The AAPS Journal

, Volume 8, Issue 4, pp E682–E692

Vesicular monoamine transporter 2: Role as a novel target for drug development

  • Guangrong Zheng
  • Linda P. Dwoskin
  • Peter A. Crooks
Article

Abstract

In the central nervous, system, vesicular monoamine transporter 2 (VMAT2) is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles for storage and subsequent exocytotic release. Pharmacologically enhancing DA sequenstration by VMAT2, and thus preventing the oxidation of DA in the cytoplasm, may be a strategy for treating diseases such as Parkinson's disease. VMAT2 may also be a novel target for the development of treatments for psychostimulant abuse. This review summarizes the possible role of VMAT2 as a therapeutic target, VMAT2 ligands reported in the literature, and the structure-activity relationship of these ligands, including tetrabenazine analogs, ketanserin analogs, lobeline analogs, and 3-amine-2-phenylpropene analogs. The molecular structure of VMAT2 and its relevance to ligand binding are briefly discussed.

Keywords

vesicular monoamine transporter 2 Parkinson's disease psychostimulant abuse tetrabenazine ketanserin lobeline 

Copyright information

© American Association of Pharmaceutical Scientists 2006

Authors and Affiliations

  • Guangrong Zheng
    • 1
  • Linda P. Dwoskin
    • 1
  • Peter A. Crooks
    • 1
  1. 1.College of PharmacyUniversity of Kentucky, Department of Pharmaceutical SciencesLexington

Personalised recommendations